STAT Plus: Celgene is perking up. Here’s what needs to happen for the momentum to continue

Celgene is getting a pipeline confidence boost courtesy of its friends at Acceleron Pharma. Next, Celgene can help itself by raising financial guidance for the rest of the year.

On Monday night, Celgene and Acceleron said their partnered drug luspatercept met all primary and secondary endpoints in a Phase 3 clinical trial of patients with transfusion-dependent beta thalassemia. The good news was a fast follow to a similar win for luspatercept in a Phase 3 trial involving patients with another blood disease — myelodysplastic syndrome.

Continue to STAT Plus to read the full story…

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button